Sigmoid is a European SME based in Dublin, Ireland. It has 20 staff and has developed an innovative oral drug delivery technology SmPill®, the primary application of which is the development of novel therapeutics to treat gastrointestinal diseases such as ulcerative colitis and Crohn’s disease. The lead product has successfully completed Phase IIa human clinical trial.
Sigmoid operates a GMP facility and won the 2010 Irish Innovation of the Year Award for the development of a novel product for the treatment of ulcerative colitis. Sigmoid has proven capability in the management of complex collaborations and has developed an expertise in translational research, working closely with academic groups, developing and testing novel SmPill®-based products and thereafter conducting human clinical studies. Sigmoid Pharma is headquartered at the “Invent Centre” advanced technologies incubator on the campus of Dublin City University in Ireland’s capital city.
Sigmoid is privately financed and is led by an experienced team of senior executives.
We see the proposed project as an excellent opportunity to engage with academic and industry partners across Europe; to influence academic pharmacy curricula at the undergraduate, postgraduate and CPD level and share our experience in pharmaceutical development, manufacture and pharmaceutical innovation.
Rosemarie Tully, Chief Business Officer
Dr. Monica Rosa, Head of Production